Viyash Scientific Limited (formerly Sequent Scientific Limited) announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company's Board of Directors, in a meeting held on February 5, 2026, also approved the introduction of the "Viyash Scientific Limited Employee Stock Option Scheme 2026" (VSL ESOP Scheme 2026), subject to necessary approvals. This new scheme aims to align with post-merger strategic objectives and operational requirements. Additionally, the Board approved changes in Senior Management Personnel (SMP) effective February 5, 2026, following a comprehensive review of leadership roles. New SMPs appointed include Mr. Attanti Veera Venkata Srinivasa Rao (VP, R&D (API)), Mr. Nrusimha Srinivasa Rao Bondalapati (VP, Quality & Regulatory), and Mr. Peddanna Gumudavelli (COO, Appco Pharma LLC). Mr. Pradip Natarajan will cease to be an SMP while continuing his employment. The company also disclosed the contact details of Directors/Key Managerial Personnel authorized to determine the materiality of events for disclosures. The financial results show that for the quarter ended December 31, 2025, consolidated revenue from operations was ₹8,584.10 crore, and profit before tax was ₹1,143.30 crore. For the nine months ended December 31, 2025, consolidated revenue from operations was ₹25,003.50 crore, and profit before tax was ₹2,679.90 crore. Standalone revenue from operations for the quarter was ₹3,416.40 crore, with profit before tax at ₹106.10 crore. For the nine months ended December 31, 2025, standalone revenue was ₹10,095.70 crore, and profit before tax was ₹674.70 crore. The financial statements reflect the impact of the Composite Scheme of Amalgamation, which became effective on December 16, 2025.
